These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 32805361)

  • 1. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
    Margolskee A; Darwich AS; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Laplanche L; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():610-625. PubMed ID: 27816631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
    Darwich AS; Margolskee A; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():626-642. PubMed ID: 27693299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.
    Margolskee A; Darwich AS; Pepin X; Pathak SM; Bolger MB; Aarons L; Rostami-Hodjegan A; Angstenberger J; Graf F; Laplanche L; Müller T; Carlert S; Daga P; Murphy D; Tannergren C; Yasin M; Greschat-Schade S; Mück W; Muenster U; van der Mey D; Frank KJ; Lloyd R; Adriaenssen L; Bevernage J; De Zwart L; Swerts D; Tistaert C; Van Den Bergh A; Van Peer A; Beato S; Nguyen-Trung AT; Bennett J; McAllister M; Wong M; Zane P; Ollier C; Vicat P; Kolhmann M; Marker A; Brun P; Mazuir F; Beilles S; Venczel M; Boulenc X; Loos P; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():598-609. PubMed ID: 27671970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models.
    Sjögren E; Thörn H; Tannergren C
    Mol Pharm; 2016 Jun; 13(6):1763-78. PubMed ID: 26926043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
    Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J
    J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
    Jadhav H; Augustijns P; Tannergren C
    Mol Pharm; 2023 Dec; 20(12):6272-6288. PubMed ID: 37902586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling.
    Eriksson J; Thörn H; Lennernäs H; Sjögren E
    Eur J Pharm Biopharm; 2020 Nov; 156():191-202. PubMed ID: 32941997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.
    Lennernäs H; Lindahl A; Van Peer A; Ollier C; Flanagan T; Lionberger R; Nordmark A; Yamashita S; Yu L; Amidon GL; Fischer V; Sjögren E; Zane P; McAllister M; Abrahamsson B
    Mol Pharm; 2017 Apr; 14(4):1307-1314. PubMed ID: 28195732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
    Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
    Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
    Zhang T; Heimbach T; Lin W; Zhang J; He H
    J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®.
    Cuquerella-Gilabert M; Reig-López J; Serna J; Rueda-Ferreiro A; Merino-Sanjuan M; Mangas-Sanjuan V; Sánchez-Herrero S
    Comput Methods Programs Biomed; 2024 Jan; 243():107929. PubMed ID: 38006685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.